Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025 | Taiwan News | Oct. 31, 2025 14:35

Contributing sentiments towards policy:

52% : First patient dosed in Phase 2a trial of investigational cancer immunotherapy HTL0039732 HTL0039732 (also known as NXE0039732) is Nxera's novel oral EP4 antagonist being investigated to treat a wide range of solid cancers in combination with other immunotherapiesCancer Research UK's Centre for Drug Development is sponsoring and managing the ongoing trial Second R&D milestone reached under Nxera's multi-target discovery collaboration with AbbVie, resulting in a payment of US$10 million to the Company Collaboration aims to leverage Nxera's NxWave™ platform to discover, develop and commercialize new medicines targeting novel GPCR targets associated with neurological disease Post-period events Nxera's partner Cancer Research UK presented data from the successfully completed Phase 1 clinical trial of HTL'732 at the European Society for Medical Oncology Congress (ESMO) 2025 HTL'732 was well-tolerated, confirmed target engagement and demonstrated encouraging early efficacy in two distinct tumor types when administered in combination with atezolizumabThe Phase 1 trial met the key objectives and identified a dose for the Phase 2 expansion trial which is now underway Manufacturing approval partial amendment from Japan's Ministry of Health, Labour and Welfare for an additional manufacturing site in Asia for QUVIVIQ 25 and 50mg Expected to improve profitability through manufacturing cost reductions to advance toward 2030 vision Financial Highlights for the Nine-month Period ended 30 September 2025 Revenue totalled JPY 21,848 million (US$147.4 million*), a decrease of JPY 135 million (an increase of US$2.0 million) vs. the prior corresponding period.
43% : This change in profitability reflects the combined effect of all movements explained above.Loss before income tax totalled JPY 6,838 million (US$46.1 million) vs. a loss before income tax of JPY 2,293 million (US$15.2 million) in the prior corresponding period.Net loss totalled JPY 4,809 million (US$32.5 million) vs. a net loss of JPY 3,503 million (US$23.2 million) in the prior corresponding period.Core operating loss** totalled JPY 986 million (US$6.6 million) vs. a core operating profit of JPY 4,425 million (US$29.3 million) in the prior corresponding period.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.